Gunderson Dettmer has advised Hims & Hers. Latham & Watkins has advised GRAIL, Inc. GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect...
GRAIL Announces $325 Million Private Placement
Surrozen’s $175 Million Oversubscribed Private Placement
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented The Column Group in the transaction. Surrozen (Nasdaq: SRZN), a biotechnology company pioneering Wnt pathway-based therapeutics, announced it...
Flywire’s $256 Million Common Stock Offering
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian acted as counsel to Flywire, and Goodwin Procter acted as counsel to the underwriters. Flywire Corporation (Nasdaq: FLYW) announced its underwritten...
AltC Acquisition Corp.’s Business Combination with Oklo
Weil, Gotshal & Manges LLP represented AltC Acquisition Corp., while Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP represented Oklo Inc. in the transaction. An advanced...
Alimera Sciences’ Acquisition of U.S. Commercial Rights to YUTIQ®
Gunderson Dettmer represented Alimera Sciences on the transaction, while Sidley Austin LLP represented EyePoint Pharmaceuticals, Inc. Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company, has...
GSK’s $3.3 Billion Acquisition of Affinivax
Davis Polk advised GSK plc on the deal while Gunderson Dettmer represented Affinivax. GSK plc announced its acquisition of Affinivax, Inc. for a $2.1 billion upfront...
Synchronoss’ Two Public Offerings and Private Placement
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Synchronoss on the deal. Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and...
Flywire’s IPO
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP advised Flywire on the deal. Boston-based global payments enablement and software company, Flywire, announced its initial public offering. The company...